Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

被引:5
|
作者
Toss, Angela [1 ,2 ]
Venturelli, Marta [1 ]
Civallero, Monica [3 ]
Piombino, Claudia [1 ]
Domati, Federica [2 ]
Ficarra, Guido [4 ]
Combi, Francesca [5 ,6 ]
Cabitza, Eleonora [1 ]
Caggia, Federica [1 ]
Barbieri, Elena [1 ]
Barbolini, Monica [1 ]
Moscetti, Luca [1 ]
Omarini, Claudia [1 ]
Piacentini, Federico [1 ,2 ]
Tazzioli, Giovanni [2 ,5 ]
Dominici, Massimo [1 ,2 ]
Cortesi, Laura [1 ]
机构
[1] Azienda Osped Univ Modena, Dept Oncol & Hematol, Modena, Italy
[2] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci Transplant Surg O, Modena, Italy
[4] Univ Hosp Modena, Pathol Unit, Modena, Italy
[5] Azienda Osped Univ Modena, Unit Breast Surg Oncol, Modena, Italy
[6] Univ Modena & Reggio Emilia, Int Doctorate Sch Clin & Expt Med, Dept Biomed Metab & Neural Sci, Modena, Italy
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
triple-negative breast cancer; neoadjuvant chemotherapy; pathologic response; residual cancer burden (RCB); multifocal disease; TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; SURVIVAL; CARBOPLATIN; RECURRENCE; PATTERNS; SURGERY; THERAPY; DISTANT; DISEASE;
D O I
10.3389/fonc.2022.1016295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionTriple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for relapse in this subset of patients are poorly characterized. This study aimed to identify the predictive factors for relapse in TNBC patients without pCR after NACT. MethodsWomen with TNBC treated with NACT from January 2008 to May 2020 at the Modena Cancer Center were included in the analysis. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of relapse. ResultsWe identified 142 patients with a median follow-up of 55 months. After NACT, 62 patients obtained pCR (43.9%). Young age at diagnosis (<50 years) and high Ki-67 (20%) were signi!cantly associated with pCR. Lack of pCR after NACT resulted in worse 5-year event-free survival (EFS) and overall survival (OS). Factors independently predicting EFS in patients without pCR were the presence of multifocal disease [hazard ratio (HR), 3.77; 95% CI, 1.45-9.61; p=0.005] and residual cancer burden (RCB) III (HR, 3.04; 95% CI, 1.09-9.9; p=0.04). Neither germline BRCA status nor HER2-low expression were associated with relapse. DiscussionThese data can be used to stratify patients and potentially guide treatment decision-making, identifying appropriate candidates for treatment intensi!cation especially in neo-/adjuvant setting.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Predictive factors of pathological complete response to neoadjuvant therapy in triple-negative breast carcinoma
    Costa, J.
    Coimbra, N.
    Lopes, P.
    Antunes, L.
    Souto Moura, M.
    Leal, C.
    [J]. VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [2] Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
    Lejeune, Marylene
    Reverte, Laia
    Sauras, Esther
    Gallardo, Noelia
    Bosch, Ramon
    Roso, Albert
    Petit, Anna
    Peg, Vicente
    Riu, Francisco
    Garcia-Fontgivell, Joan
    Ibanez, Jose
    Relea, Fernanda
    Vieites, Begona
    Bor, Catherine
    de la Cruz-Merino, Luis
    Arenas, Meritxell
    Rodriguez, Valerie
    Galera, Juana
    Korzynska, Anna
    Belhomme, Philippe
    Plancoulaine, Benoit
    alvaro, Tomas
    Lopez, Carlos
    [J]. CANCERS, 2023, 15 (03)
  • [3] Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Nakashoji, Ayako
    Matsui, Akira
    Nagayama, Aiko
    Iwata, Yuko
    Sasahara, Manami
    Murata, Yuya
    [J]. ONCOLOGY LETTERS, 2017, 14 (04) : 4135 - 4141
  • [5] Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
    Li, JunJie
    Chen, Sheng
    Chen, CanMing
    Di, GenHong
    Liu, GuangYu
    Wu, Jiong
    Shao, ZhiMin
    [J]. ONCOTARGET, 2017, 8 (11) : 18399 - 18408
  • [6] A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Chen, Xi
    Zhou, Zhiguo
    [J]. CANCER RESEARCH, 2024, 84 (03)
  • [7] Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer
    Van Bockstal, Mieke R.
    Noel, Fanchon
    Guiot, Yves
    Duhoux, Francois P.
    Mazzeo, Filomena
    Van Marcke, Cedric
    Fellah, Latifa
    Ledoux, Benjamin
    Berliere, Martine
    Galant, Christine
    [J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 49
  • [8] Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients
    Masuda, Hiroko
    Masuda, Norikazu
    Kodama, Yoshinori
    Ogawa, Masami
    Karita, Michiko
    Yamamura, Jun
    Tsukuda, Kazunori
    Doihara, Hiroyoshi
    Miyoshi, Shinichiro
    Mano, Masayuki
    Nakamori, Shoji
    Tsujinaka, Toshimasa
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 911 - 917
  • [9] Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients
    Hiroko Masuda
    Norikazu Masuda
    Yoshinori Kodama
    Masami Ogawa
    Michiko Karita
    Jun Yamamura
    Kazunori Tsukuda
    Hiroyoshi Doihara
    Shinichiro Miyoshi
    Masayuki Mano
    Shoji Nakamori
    Toshimasa Tsujinaka
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 911 - 917
  • [10] Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy
    Kennedy, William R.
    Tricarico, Christopher
    Gabani, Prashant
    Weiner, Ashley A.
    Altman, Michael B.
    Ochoa, Laura L.
    Thomas, Maria A.
    Margenthaler, Julie A.
    Sanati, Souzan
    Peterson, Lindsay L.
    Ma, Cynthia X.
    Ademuyiwa, Foluso O.
    Zoberi, Imran
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (03): : 288 - 296